Other markers potentially eligible for target therapies include FRalpha (a recent study investigated in vitro and in vivo activity of IMGN853, a drug targeting this biomarker in biologically aggressive endometrial cancers) [108] and NEK2 (inhibition of its kinase activity has been studied in preclinical studies with MBM-5) [109]. Here, FOLR1 is linked to endometrial cancer.